| 000 | 01614 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514225023.0 | ||
| 264 | 0 | _c20050819 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a1084-9785 | ||
| 024 | 7 |
_a10.1089/cbr.2005.20.195 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGaze, Mark N | |
| 245 | 0 | 0 |
_aFeasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. _h[electronic resource] |
| 260 |
_bCancer biotherapy & radiopharmaceuticals _cApr 2005 |
||
| 300 |
_a195-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_a3-Iodobenzylguanidine _xpharmacology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDose-Response Relationship, Radiation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIodine Radioisotopes _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 |
_aNeuroblastoma _xtherapy |
| 650 | 0 | 4 | _aRadiation Dosage |
| 650 | 0 | 4 |
_aRadiation-Sensitizing Agents _xpharmacology |
| 650 | 0 | 4 |
_aRadiometry _xmethods |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xpharmacology |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 |
_aTopotecan _xpharmacology |
| 650 | 0 | 4 | _aWhole-Body Counting |
| 700 | 1 | _aChang, Yen-Ch'ing | |
| 700 | 1 | _aFlux, Glenn D | |
| 700 | 1 | _aMairs, Rob J | |
| 700 | 1 | _aSaran, Frank H | |
| 700 | 1 | _aMeller, Simon T | |
| 773 | 0 |
_tCancer biotherapy & radiopharmaceuticals _gvol. 20 _gno. 2 _gp. 195-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/cbr.2005.20.195 _zAvailable from publisher's website |
| 999 |
_c15535577 _d15535577 |
||